By Lucy Caulkett-
Recent breakthroughs in medical science have introduced pioneering new treatments that are reversing previously incurable blood diseases and cancers in some patients. These innovations represent a paradigm shift, moving the focus from merely managing chronic, life-limiting conditions toward achieving long-term remission and potentially a functional cure.
From gene-edited immune cells described as a “living drug” to “Trojan horse” targeted therapies and one-time infusions for genetic disorders, these advances are offering new hope where traditional medicine had limited options.
AD: Capeesh Restaurant
One of the most remarkable recent developments is the use of an innovative, “off-the-shelf” cell therapy known as BE-CAR7, which employs base editing technology to create universal, cancer-fighting immune cells. This ground breaking approach has shown impressive responses in clearing leukaemia that was previously considered incurable.
The therapy first made headlines when it was successfully administered to Alyssa Tapley, who was diagnosed with T-cell leukaemia in May 2021. After her cancer failed to respond to standard treatments, including chemotherapy, palliative care seemed the only remaining option.
However, at just 13 years old, Alyssa became the first person in the world to receive the experimental BE-CAR7 treatment at Great Ormond Street Hospital in London.
Following this treatment, Alyssa is doing exceptionally well and is considered cancer-free. Her successful outcome provided a significant proof of concept for this technology.
AD: Oysterian Sea Food Restaurant And Bar
BE-CAR7 is a type of CAR T-cell therapy that uses healthy donor T-cells, modified using base editing, to create a universal treatment that can be quickly deployed when a patient needs it.
Key modifications include disabling the targeting mechanism to prevent the cells from attacking healthy tissues, removing a marker to stop the treatment from targeting itself, and making the cells resistant to a specific chemotherapy drug. Clinical trials using this approach have demonstrated “impressive responses” in treating previously incurable leukaemia.
The “Trojan Horse” Therapy: A New Weapon Against Multiple Myeloma
For multiple myeloma, an incurable bone marrow cancer, a “Trojan horse” therapy called belantamab mafodotin has become a new treatment option.
Developed by GSK, is a therapy is an antibody-drug conjugate (ADC). The antibody targets a protein (BCMA) on myeloma cells, allowing the entire complex to be absorbed by the cancer cell. Once inside, a potent chemotherapy payload is released, destroying the cell from within.
This method delivers chemotherapy directly to cancer cells while minimizing harm to healthy tissue, leading to fewer side effects. Common side effects include eye issues like dryness and blurred vision.
Clinical trials showed this therapy halted cancer progression for significantly longer than previous treatments, offering “life-changing” results for patients. One patient in remission after receiving the therapy described it as a “second go at life”.
This therapy is available for approximately 1,500 eligible patients annually in England. While myeloma is still incurable, experts see such drugs as progress towards a “functional cure”.
The field of blood disorder treatment is rapidly advancing, utilizing the immune system and developing highly specific therapies.
Personalized CAR T-cell therapy, where a patient’s own T-cells are modified to target cancer, is increasingly available. This treatment is approved for certain B-cell lymphomas and acute lymphoblastic leukaemia (ALL) when other treatments fail, with success rates varying but offering considerable hope.
Newer therapies like obe-cel for adult B-cell ALL and glofitamab, which helps immune cells fight cancer, are also being explored or recommended. Novel Oral Formulations and Targeted Drugs
New medications, including convenient oral options, are also emerging:
Oral Arsenic Trioxide (Oral-ATO): A new oral formulation for acute promyelocytic leukaemia (APL) with a high cure rate, potentially reducing the need for chemotherapy or transplants.
An investigational “degrader” drug for chronic lymphocytic leukaemia (CLL) that targets the protein responsible for cancer growth.
Breakthroughs are also occurring for genetic blood conditions. Lovotibeglogene autotemcel is a one-time gene therapy for sickle cell anaemia. This therapy modifies a patient’s stem cells and reintroduces them after chemotherapy.
Clinical trials show a high percentage of participants achieving complete symptom resolution, effectively curing the underlying cause. However, the high cost of this treatment presents a significant accessibility challenge.
The treatments discussed highlight a promising era in medicine where conditions previously considered incurable are becoming treatable, manageable, and sometimes curable.
Targeted therapies, immunotherapies, and gene editing are transforming patient outcomes. Examples include therapies for multiple myeloma, leukaemia, and sickle cell anaemia. Ongoing research aims to develop gentler and more effective treatments, moving towards a future where blood cancers and diseases are no longer a life-threatening diagnosis.
AD: Heritage And Restaurant Lounge Bar